The U.S. Food and Drug Administration issues draft guidance for industry and agency staff titled “Highly Multiplexed Microbiological/Medical Countermeasure in Vitro Nucleic Acid Based Diagnostic Devices.” The draft includes recommendations for studies to establish the analytical and clinical performance of these devices. Comments are requested by February 7, 2013.